Are you Dr. Leopold?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 72 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1441 Catlin Way
Dresher, PA 19025Phone+1 610-203-9328Fax+1 866-305-6063- Is this information wrong?
Summary
- Dr. Lance Leopold, MD is an oncologist in Dresher, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
- Temple University HospitalFellowship, Hematology and Medical Oncology, 1990 - 1993
- Temple University HospitalResidency, Internal Medicine, 1987 - 1990
- Lewis Katz School of Medicine at Temple UniversityClass of 1987
Certifications & Licensure
- PA State Medical License 1989 - 2024
Clinical Trials
- Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies Start of enrollment: 2005 Nov 01
- Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC Start of enrollment: 2006 Feb 01
- A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer Start of enrollment: 2005 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsExploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase...Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, Patricia M LoRusso, Ignacio Garrido-Laguna, Lanc...> ;Journal for Immunotherapy of Cancer. 2022 Mar 1
- 231 citationsEpacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)Tara C. Mitchell, Omid Hamid, David Smith, Todd M. Bauer, Jeffrey S. Wasser, Anthony J. Olszanski, Jason J. Luke, Ani Sarkis Balmanoukian, Emmett V. Schmidt, Yufan Zha...> ;Journal of Clinical Oncology. 2018 Sep 28
- 195 citationsFirst-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.Gregory L. Beatty, Peter J. O'Dwyer, Jason Clark, Jack G. Shi, Kevin Bowman, Peggy Scherle, Robert C. Newton, Richard Schaub, Janet Maleski, Lance Leopold, Thomas F. G...> ;Clinical Cancer Research. 2017 Jul 1
- Join now to see all
Press Mentions
- Incyte and Mirati Therapeutics Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid TumorsNovember 7th, 2022
- Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)June 24th, 2021
- Incyte Announces the Validation by the European Medicines Agency of Its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)February 26th, 2021
- Join now to see all